Expert on Demand in
Triple Negative Breast Cancer (TNBC)

The Expert on Demand programme at MSD provides an exciting opportunity for you and your MDT to connect with Key opinion leaders in TNBC at a time that works for you.

KEYconversations in early-stage TNBC.

How to sign up?

  • Choose your module
  • Complete the form below to express your interest
  • You will be contacted by your local MSD representative to arrange a suitable time and date

Read more about the available modules in TNBC below:

Can We Change Treatment
Outcomes in TNBC?

This module provides an overview of the KEYNOTE-522 study, focuses on eligible patients for this treatment regimen and looks at the original and updated trial results. Our expert speakers will also be able to share best practice on implementing this regimen in your hospital.

Learning Objectives – To enhance knowledge around the…

  • Factors to consider when initiating treatment of early-stage TNBC
  • Potential barriers to the use of neoadjuvant/adjuvant therapy in TNBC
  • Use of pembrolizumab as neoadjuvant/adjuvant treatment in TNBC (using key data from KEYNOTE-522)


Dr Mukesh

Dr Mukesh Mukesh

East Suffolk and North Essex NHS Trust


Dr Mukesh graduated from medical school in India in 2003 with distinction and undertook specialist training in Clinical Oncology at Cambridge. He completed MSc in Oncology from the Institute of Cancer Research, London with distinction & Fellowship of the Royal College of Radiologists in 2010. He completed Doctorate of Medicine (MD) with Ralph Noble prize from the University of Cambridge in 2018 for breast radiotherapy research. 
He is a consultant Clinical Oncologist at East Suffolk & North Essex NHS Trust specialising in breast cancer and melanoma. His clinical interest includes clinical trials, immunotherapy & personalised cancer therapy.  

Dr Phillips

Dr Melissa Phillips

Barts Cancer Institute, London


Dr Phillips is a Consultant Medical Oncologist at St Bartholomew’s Hospital, London, specialising in breast cancer. She studied medicine at King’s College London and subsequently completed her general medical training at Imperial College Healthcare NHS Trust and her specialist training in medical oncology at Barts Health NHS Trust. In 2010 she undertook a PhD in Molecular Oncology, investigating the role of the tumour microenvironment in drug resistance. Her current role focuses on the management of breast cancer. She is a Principle and Co-investigator on a variety of clinical trials in early and metastatic breast cancer. She has authored or co-authored a number of publications and has presented at local and national conferences. She has particular interest in the management of early breast cancer.

Identifying and Managing
Adverse Events in TNBC

This module provides a deep dive into the adverse event profile for KEYNOTE-522 and best practice on how to manage immune-mediated adverse events in your hospital.

Learning Objectives – To enhance knowledge around the…

  • Impact of neoadjuvant/adjuvant pembrolizumab on the adverse event profile in TNBC
  • Common immune-mediated AEs and the challenges in identification and management
  • How to optimise management of immune-mediated AEs through communication and collaboration


Dr Raja

Dr Fharat Raja

University College London Hospital NHS Foundation Trust


Dr Raja graduated in medicine from Oxford University before carrying out post-graduate training in medical oncology at University College London (UCL) Hospital and Mount Vernon Cancer centre. From 2009 to 2013, Dr Raja was a Research Clinical Fellow at the Medical Research Council Clinical Trials Unit and UCL Cancer Trials Centre. Specialising in Breast Cancer and Acute Oncology, Dr Raja is a Clinical Lead for Acute Oncology at the North Middlesex Hospital as well as the Principal Investigator of several national and international trials. She has publications in a number of peer reviewed journals including the Lancet, Annals of Oncology and British Journal of Cancer and is a Trustee of Future Dreams Breast Cancer Charity; a charity raising funds to support women through their breast cancer journey.

Dr Wheatley

Dr Duncan Wheatley

Royal Cornwall Hospital NHS Trust


Dr Wheatley is a Consultant in Clinical Oncology, specialising in Breast and Urological tumours. He is also the Clinical Director of Research and Innovation at the Royal Cornwall Hospital and for many years has been Clinical Lead for National Cancer Research Institute (NCRI) Cancer research in the SW Peninsula, as well as sitting on the NCRI Breast Clinical Studies Group and being an honorary senior lecturer at Exeter University. Dr Wheatley took up a Clinical Oncology Consultancy position at the new Royal Cornwall Hospital Cancer Centre in Truro in 2002. His clinical research consists of co-authoring 22 peer reviewed articles and experience in the roles of Chief Investigator and Principal Investigator on many studies, most recently being chief clinical co-ordinator of the FAST Forward Study. Dr Wheatley is a Trustee and Membership Secretary for UK Breast Cancer Group (UKBCG).

Enhancing Treatment and Decision-making for TNBC Patients 

This module focuses on the impact of the KEYNOTE-522 regimen on the treatment landscape in Breast Cancer. Our expert speakers will provide an overview of the KEYNOTE-522 data and the practical implications to consider as an MDT before, during and after surgery

Learning Objectives –

  • Discuss the evolving surgical and medical treatment landscape for early-stage TNBC
  • Understand the unmet need for neoadjuvant systemic anti-cancer therapy beyond surgical outcomes
  • Discuss the data, rationale, and patient eligibility for immunotherapy as neoadjuvant and adjuvant treatment in early-stage TNBC, and related AE management
  • Build collaboration and communication in the surgical and oncological treatment of TNBC


Mr Cain

Mr Henry Cain

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle


Mr Cain is an established consultant Oncoplastic Breast Surgeon with specialist research interest in the molecular basis of breast cancer and the use of neoadjuvant chemotherapy. He provides specialist expertise and services in breast and reconstructive surgery for patients with breast cancer and is the surgical lead for the teenage and young adult breast cancer service. Mr Cain qualified in 2001 from Leicester, completed his surgical training in the North of England, and following the award of MD in breast cancer signalling pathways and higher surgical training he spent a year as the Oncoplastic Fellow at the Canniesburn Unit in Glasgow. In 2013, he was appointed a Consultant Oncoplastic surgeon at the Royal Victoria Infirmary Newcastle upon Tyne.
Mr Cain participates in numerous research activities whilst maintaining a commitment to teaching advanced oncoplastic breast surgery. He has delivered various clinical trials including LORIS, ATNEC, HORIZON and the SMALL trial and is the chief investigator of the multi centre randomised control trial PRE-DX. He is also the surgical lead for the national NOSTRA study. His area of interest is the development of clinical strategies for the delivery of new breast cancer therapies.

Mr McIntosh

Mr Stuart McIntosh

Belfast City Hospital


Mr McIntosh is a Clinical Reader in Surgical Oncology at Queen’s University in Belfast, and an honorary consultant breast surgeon at Belfast City Hospital. He graduated from Edinburgh University in 1993, completing general surgical training in the North-East of Scotland, moving to Belfast in 2009, and to an academic position in 2015. He has been a consultant oncoplastic and reconstructive breast surgeon since 2005, with extensive clinical experience in the management of both breast cancer and benign breast conditions. He is an experienced breast cancer clinical trialist, having contributed to numerous trials in early breast cancer, with a particular emphasis on neoadjuvant, peri-surgical and treatment de-escalation studies. He is the Chief Investigator for the UK HTA funded SMALL trial, a national phase III multicentre study comparing standard surgery with vacuum-assisted excision for the treatment of small screen-detected breast cancers.His translational research interests lie in the area of the DNA damage immune response in breast cancer. He is Chair of the UK National Cancer Research Institute Breast Research Group and a member of the NCRI Strategic Advisory Group, and he has an excellent overview of the portfolio of clinical and translational breast cancer research in the UK. In his role as the Royal College of Surgeons Breast Surgical Specialty Lead, he is responsible for supporting the development and delivery of breast cancer trials nationally, with a specific emphasis on surgical studies. In addition, he is also Clinical Director for the Northern Ireland Cancer Trials Network, responsible for overseeing delivery of cancer clinical research across the five cancer hospitals in Northern Ireland.

KEYTRUDA (pembrolizumab) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.1

Please refer to the SmPC for further information before making any prescribing decisions.


  1. KEYTRUDA Summary of Product Characteristics

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

To register your interest in Expert on Demand please complete the form below:

Read about the modules here

MSD will only use this information for the purpose of responding to your inquiry and it will not be stored for any other use. MSD will not pass your information on to a third party organisation. This form is not intended for the reporting of adverse events or medical information.The reporting form and MSD Medical Information contact details can be found at the end of this page.

This field is for validation purposes and should be left unchanged.